METTL3 Inhibition Induced by M2 Macrophage-Derived Extracellular Vesicles Drives Anti-PD-1 Therapy Resistance via M6A-CD70-Mediated Immune Suppression in Thyroid Cancer

Scientists revealed that low METTL3 expression correlated with poor response to immune checkpoint blockade, and overexpressing METTL3 in tumor cells could enhance the efficacy of anti-PD-1 therapy in papillary thyroid cancer and anaplastic thyroid cancer.